Physician profile
Noel Maun
NPI 1518940246
$5,099.56
in general payments reported to CMS, 2019-2025
45 companies · $1,130 in 2025
The $1,130 reported for 2025 was less than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $467 · 2020: $255 · 2021: $321 · 2022: $1,082 · 2023: $783 · 2024: $1,061 · 2025: $1,130.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,849 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $125.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,849.32 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $125.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $594.51 | 2019-2025 | Keytruda, Lynparza, Keytruda Qlex |
| Celgene Corporation | $410.63 | 2021-2024 | Reblozyl, Opdualag, Pomalyst |
| E.R. Squibb & Sons, L.L.C. | $352.83 | 2019-2025 | Opdivo |
| Janssen Biotech, INC. | $302.07 | 2019-2025 | Darzalex, Imbruvica, Tecvayli |
| Beigene USA, INC. | $267.76 | 2022-2024 | Brukinsa |
| Pfizer INC. | $263.69 | 2019-2025 | |
| Daiichi Sankyo INC. | $246.93 | 2022-2025 | Enhertu |
| Gilead Sciences, INC. | $218.78 | 2021-2025 | Trodelvy |
| Astellas Pharma US INC | $183.34 | 2019-2025 | Padcev, Xospata, Vyloy |
| Novartis Pharmaceuticals Corporation | $179.75 | 2019-2025 | |
| Genzyme Corporation | $171.37 | 2019-2025 | |
| Acrotech Biopharma INC. | $146.97 | 2024-2025 | Beleodaq |
| Glaxosmithkline, LLC. | $143.73 | 2022-2025 | Ojjaara |
| Intuitive Surgical, INC. | $134.61 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $133.75 | 2024 |
Show all 45 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Noel Maun listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.